Advancing Small Nucleic Acid Drug Development with a One-Stop Solution

Small nucleic acid drugs, such as siRNA, ASO (anti-sense oligonucleotides), miRNA and aptamers, function by binding to and inhibit the activity of RNA through a process known as RNA interference (RNAi). This class of molecules offer many advantages over traditional pharmaceuticals: unlimited target selection, high specificity, long half-life, ease of design and fast development and production processes.

In this webinar, we will discuss recent advances in the development of small nucleic acid drugs and explain how GenScript's one-stop solution, from design and synthesis to analysis, screening, verification and delivery can accelerate your research.

• Date: April 21^th 2025
• Time: 10:00 am EDT (NA) / 7:00 am PST (NA) / 3:00pm BST (UK) / 4:00pm CEST (EU-Central)

Mark Shulewitz, PhD, Field Application Scientist – Life Science Group

• Earned a PhD from the University of California, Berkeley and is an expert in Molecular Biology, with publications in journals such as Oncogene.
• Held key roles in the R&D and commercial teams of leading biotechnology companies, including Genentech, Inc., PDL BioPharma, Inc., and Bio-Rad, Inc.
• Possesses extensive experience with siRNA, particularly in developing cell-based assays for antibody discovery, development, and validation. Successfully developed and launched numerous products for Life Science Research.
• At GenScript, Mark brings his deep experience as a bench scientist to his role as a Field Application Scientist, where he successfully provided technical consultation for multiple siRNA projects, supporting their efficient progress.

Speaker-related Webinars

Advancing Small Nucleic Acid Drug Development with a One-Stop Solution

Small nucleic acid drugs, such as siRNA, ASO (anti-sense oligonucleotides), miRNA and aptamers, function by binding to and inhibit the activity of RNA through a process known as RNA interference (RNAi). This class of molecules offer many advantages over t

Learn More